About Event

The Only For-Industry, Drug Development-First, Gene Editing Summit

The toolbox of precision genome editing and delivery techniques continued to grow in 2024, enabling the community to make safer and more precise edits to a wider variety of disease targets. Translating these exciting technologies into viable therapeutic programs, however, relied on multidisciplinary technical and strategic expertise across areas in which the gene editing field was still in its infancy.

The 2024 Genome Editing Therapeutics Summit enabled attendees to develop, translate, and deliver novel gene editing technologies in the therapeutic setting, providing the latest data from exciting preclinical and clinical programs, and strategies on the following key topic areas:

Enabling precise small and large DNA fragment insertion: Comprehensively covered the latest platform development and drug development challenges associated with recombinase- and transposon-based editing technologies.

 

Improving the robustness of your nonclinical and clinical safety packages: Navigated safety and toxicity risks, advanced your on- and off-target detection strategy, and ensured clinical safety monitoring.

 

Unlocking efficient, cell- and tissue-specific delivery: Progressed lipid nanoparticles for extrahepatic delivery, overcame translational challenges of novel delivery vehicles, and tackled scale-up challenges.

 

Leveraging regulatory insights to progress to the clinic: Learned how to facilitate a successful IND submission, understood important FDA requirements ahead of commencing first-in-human trials, and unpicked new draft guidance on platform technology designations.

 

Ensuring freedom-to-operate and structuring profitable licensing deals: Developed a secure IP and patent strategy for editing and delivery technologies, established FTO as a start-up biotech, and outlined reasonable licensing deal structures.


Attendees learned from expert industry leaders, engaged in meaningful group discussions, and formed business connections with decision makers to accelerate their safe, precise, and regulatory-compliant programs into the clinic.

Johns Hopkins Uni

“The discussions and speakers were excellent” - Past Attendee, Johns Hopkins University

The 2024 Event in Numbers

120+

Attendees

70+

Attending Groups

35+

Expert Speakers

15

New Speaking Companies

12

Novel Editing and Delivery Technology Presentations

100%

Alignment with Your Drug Development Challenges

“It covered various useful topics, from new trends in the gene editing field to clinical outcomes of CRISPR application, all of which is hard to find in one conference.” - Past Attendee, CCRM

CCRM

Who Attended in 2024?

The 5th Genome Editing Therapeutics Summit was dedicated to shaping the future of the genome editing field by fostering collaboration. It attracted an audience of industry experts to ignite thought-provoking discussions that led to long-term, mutually beneficial relationships in a rapidly evolving field.

This was the only industry-led, drug development-first forum dedicated to covering the safety, precision, and strategic challenges facing the field.

Uniting 120+ leaders across R&D, Delivery, Preclinical, Translational, Clinical, and Business Development domains, this year’s summit combined both strategic and technical content to provide actionable insights for groups at different stages of the value chain, from R&D through to Clinical Development.

48775 Audience Breakdown

“Great speakers, a variety of highly relevant subjects, and a nice mix of academic and biopharma attendees”

Past Attendee, Editas Medicine

Editas Medicine